Angeion Corporation Expands International Support Through New Medical Graphics Branch Office in Milan.

SAINT PAUL, Minn. -- Angeion Corporation (NASDAQ:ANGN) announced today that its Medical Graphics business has opened a European branch office in Milan, Italy. This new office will facilitate revenue growth in international markets, provide closer marketing support to distribution partners and expand technical support for clinical research. The office will house the Minnesota-based medical device firm's business development manager, as well as technical and field service support dedicated to the Company's expanding business.

"Recent growth in our Medical Graphics international cardiorespiratory business, combined with the number of European-based clinical research sites utilizing our diagnostic systems and services, and revenue potential necessitate our presence in Europe," Rodney Young, Angeion Chief Executive Officer and President, commented. "We are excited about the future impact of our new European branch office. It expands our commitment to provide the highest quality customer care, real-time technical support on a multi-lingual basis, as well as country-specific marketing for our distribution partners. In addition to notably reducing our international travel related expenses, one of the most significant benefits of our new branch office will be our ability to provide a seamless, efficient connection between our corporate resources and our international distribution partners and end-users."

About Angeion Corporation

Founded in 1986, Angeion Corporation acquired Medical Graphics Corporation in December 1999. Medical Graphics develops, manufactures and markets non-invasive cardiorespiratory diagnostic systems that are sold under the MedGraphics (www.medgraphics.com) and New Leaf (www.newleaffitness.com) brand and trade names. These cardiorespiratory diagnostic systems have a wide range of applications in healthcare as well as health and fitness. The Company's products are sold internationally through distributors and in the United States through a direct sales force that targets heart and lung specialists located in hospitals, university-based medical centers, medical clinics and physicians' offices, pharmaceutical companies, medical device manufacturers, clinical research organizations, health and fitness clubs, personal training studios, and other exercise facilities. For more information about Angeion, visit www.angeion.com.

The discussion above contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements by their nature involve substantial risks and uncertainties. Our results may differ materially depending on a variety of factors, including: (i) our ability to successfully operate our business, including our ability to develop, improve, and update our cardiorespiratory diagnostic products, (ii) our ability to ensure constant margins for products in light of fluctuating revenues from our clinical research customers, (iii) our ability to effectively manufacture and ship our products in required quantities to meet customer demands, (iv) our ability to successfully defend the Company from product liability claims related to our cardiorespiratory diagnostic products and claims associated with our prior cardiac stimulation products, (v) our ability to protect our intellectual property, (vi) our ability to develop and maintain an effective system of internal controls and procedures and disclosure controls and procedures, and (vii) our dependence on third-party vendors. Because actual results may differ, shareholders and prospective investors are cautioned not to place undue reliance on such forward-looking statements which are qualified in their entirety by the risk factors referred to above and the other risk factors that are described from time to time in Angeion's Securities and Exchange Commission reports, including but not limited to the Annual Report on Form 10-KSB for the year ended October 31, 2006, and subsequently filed reports.